Outlook Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OTLK research report →
Companywww.outlooktherapeutics.com
Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
- CEO
- Robert Charles Jahr
- IPO
- 2016
- Employees
- 23
- HQ
- Iselin, NJ, US
Price Chart
Valuation
- Market Cap
- $10.31M
- P/E
- -0.34
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 121287.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -17.18%
- Op Margin
- -0.05%
- Net Margin
- -0.05%
- ROE
- 0.00%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $1.41M · 0.00%
- Net Income
- $-62,424,863 · 17.17%
- EPS
- $-1.79 · 55.91%
- Op Income
- $-67,061,666
- FCF YoY
- -75340109.88%
Performance & Tape
- 52W High
- $3.39
- 52W Low
- $0.16
- 50D MA
- $0.27
- 200D MA
- $1.01
- Beta
- 0.33
- Avg Volume
- 3.77M
Get TickerSpark's AI analysis on OTLK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 25 | Huang Andong | other | 286,734 |
| Oct 3, 25 | Huang Andong | other | 53,316 |
| Oct 1, 25 | Haller Julia A | other | 286,734 |
| Oct 3, 25 | Haller Julia A | other | 58,648 |
| Oct 1, 25 | HILZINGER KURT J | other | 286,734 |
| Oct 3, 25 | HILZINGER KURT J | other | 90,638 |
| Oct 1, 25 | Gangolli Julian S | other | 286,734 |
| Oct 1, 25 | Haddadin Yezan Munther | other | 286,734 |
| Oct 3, 25 | Haddadin Yezan Munther | other | 95,969 |
| Oct 1, 25 | Auffarth Gerd | other | 286,734 |
Our OTLK Coverage
We haven't published any research on OTLK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OTLK Report →